ORIGINAL

Hippocampal alteration of monoaminergic neurotransmitters biosynthesis and metabolism in CNS in rats, after prenatal and postnatal exposure to chlordimeform, through sex hormones disruption

Alteración de la síntesis y metabolismo de los neurotransmisores monoaminérgicos en el hipocampo de rata tras exposición pre y posnatal a clordimeformo por disrupción de las hormonas sexuales

María José Anadón[1], Paula Moyano[1], José Manuel García, María Teresa Frejo[2], Miguel Andrés Capó[2], Andrea Flores[2], Adela Pelayo[3], Emma Sola[3], Gloria Gómez[1], Javier del Pino[2]

1. Departamento de Toxicología y Legislación Sanitaria, Facultad de Medicina, Universidad Complutense de Madrid.
2. Departamento de Toxicología y Farmacología, Facultad de Veterinaria, Universidad Complutense de Madrid.
3. Departamento de Anatomía Patológica, Facultad de Medicina, Universidad Complutense de Madrid.

Correspondencia

Javier del Pino PhD
Departamento de Toxicología y Farmacología
Universidad Complutense de Madrid. Facultad de Veterinaria
Avda. Puerta de Hierro s/n 28040 Madrid. Spain
Tel.: 91 355 09 20 – E-mail: jdelpino@pdi.ucm.es

Abstract

Introduction: Chlordimeform, just as other formamidine pesticides, induces permanent region- and sex-dependent on monoaminergic neurotransmitter systems' development, effects that may be related to monoamine oxidase (MAO) inhibition. Nevertheless, chlordimeform is a very weak MAO inhibitor, which suggests other mechanisms' implication. In this regard, as chlordimeform alters testosterone and estradiol levels in frontal cortex and stratium, which may dysregulate the enzymes' expression that mediates the synthesis and metabolism of monoaminergic neurotransmitters systems. Thus, an alteration of these hormones and enzymes in other altered brain regions could also mediate the observed effects.

Objectives and methods: For the purpose of confirming that formamidines produce permanent alterations of monoamine neurotransmitters' systems through the disruption of sex hormones in the hipoccampus, by alteration of the expression of the enzymes that synthesize and or metabolize these neurotransmitters, hippocampus' testosterone and estradiol levels at 11 days of age, as well as the expression of MAO, COMT, BDH, TH, TRH and AD enzymes at 60 days of age after maternal exposure to chlordimeform (5mg/kg body weight) were evaluated.

Results: Our results show an important decrease in testosterone levels, in addition to a significant decrease in estradiol levels in hippocampus of rats at 11 days of age. We also observed sex interaction with treatment in the content of T and E2, and we determined a bigger increase in the expression of COMT in females than in males. Chlordimeform treatment did not alter the expression of MAO and BDH enzymes, yet decreased the expression of the TH enzyme and increased the COMT, BDH, TH and TRH enzymes in both sexes.

Conclusions: The present findings indicate that after maternal exposure to formamidines, in general, and chlordimeform, in particular, the previously mentioned compound induces a permanent alteration of monoaminergic neurotransmitters, by the alteration of the enzymes that synthetize these neurotransmitters, which is successively mediated by sex hormones disruption, in hippocampus.

Keywords: Chlordimeform; formamidines; neurodevelopmental toxicity; COMT; BDH; TH; TRH; rats; human risk assessment

Resumen

Introducción: El clordimeformo, al igual que otros plaguicidas formamidínicos, induce alteraciones permanentes de los sistemas de neurotransmisores monoaminérgicos región- y sexo-dependientes. Es posible que la inhibición de la enzima monoamino oxidasa (MAO) pueda mediar estos efectos, pero la inhibición tan leve sufrida por la MAO en presencia de este compuesto sugiere la existencia de otros mecanismos implicados. En este sentido, se ha descrito una alteración en los niveles de testosterona y estradiol en el cuerpo estriado y en la corteza frontal en presencia de clordimeformo, que puede dar lugar a una alteración de la expresión de las enzimas que sintetizan y metabolizan dichos neurotransmisores. Así, una alteración en estas hormonas y enzimas en las otras regiones afectadas también podría mediar los efectos observados en las mismas.

Objetivos y métodos: Con el objetivo de confirmar que las formamidinas causan alteraciones permanentes de los neurotransmisores monoaminérgicos mediante la disrupción de las hormonas sexuales en el hipocampo debido a la alteración de la expresión de las enzimas responsables de sintetizarlos y/o metabolizarlos, se evaluaron los efectos en el hipocampo de ratas macho y hembra

sobre los niveles de testosterona y estradiol a los 11 días de edad. Aparte, también se evaluó la expresión de las enzimas MAO, COMT, BDH, TH, TRH, y AD a los 60 días de edad tras la exposición maternal al clordimeformo (5 mg/kg de peso corporal).

Resultados: Nuestros resultados demuestran que el clordimeformo indujo, en el hipocampo de las ratas observadas a los 11 días de edad, una disminución significativa de los niveles de testosterona, así como un incremento reseñable de los niveles de estradiol. Por otro lado, se observó una interacción por sexo con el tratamiento en el contenido de T y E2 y se advirtió también una mayor expresión de las enzimas COMT [58,83% (P<0,001)], AD [46,74% (P<0,001)], TH [43,65% (P<0,001)] y TRH [37,85% (P<0,001)] en las hembras que en los machos. El tratamiento con clordimeformo no causó alteración ninguna sobre la expresión de las enzimas MAO y BDH, pero indujo una disminución en la expresión de la enzima TH y un aumento en la expresión de las enzimas COMT, BDH, y TRH tanto en machos como en hembras.

Conclusiones: Los presentes resultados indican que las formamidinas, en general, y particularmente el clordimeformo, inducen una alteración permanente de los sistemas de neurotransmisores monoaminérgicos en el cuerpo estriado tras la exposición maternal, mediante la alteración de las enzimas que metabolizan y sintetizan estos neurotransmisores, que es causada a su vez por la alteración de las hormonas sexuales.

Palabras clave: Clordimeformo; formamidinas; neurotoxicidad en el desarrollo; testosterona; estradiol; COMT; BDH; TH; TRH; ratas; evaluación del riesgo para el hombre

Introduction

Formamidine pesticides as amitraz have been described to produce permanent alterations on central nervous system's (CNS) development, like those that affect monoamine neurotransmitter systems[1]. Chlordimeform [N2-(4-chloro-o-tolyl)-N1.N1-dimethylformamidine] (**Figure 1**), which belongs to formamidine's family too, has also been reported to induce permanent alterations of serotoninergic, noradrenergic and dopaminergic systems in a region –and a sex– dependent way[2,3].

Figure 1: Chlodimeform chemical structure (C10H13Cl N2).

However, the implied mechanisms in these effects are still not clear. Monoaminergic neurotransmitters play a role during development, defined as "morphogenetic"[4-7] and changes in catecholamine levels' during brain development may induce both structural and functional alterations[8]. As formamidines have been reported to inhibit monoamine oxidase (MAO)[9-10], which participates in metabolic inactivation of the neurotransmitters serotonin (5-HT), norepinephrine (NE), and dopamine (DA), these effects may mediate the observed alterations on monoaminergic neurotransmitters. However, chlordimeform is a very weak MAO inhibitor, which could mean that other mechanisms are involved.

Conversely, formamidines are endocrine disruptors and particularly, chlordimeform and amitraz have been reported to alter serum hormone levels[19,20]. The observed alterations in NE, DA and 5-HT and its metabolites levels' observed in rats' brain after formamidines exposure may be caused by a possible change on those sex steroid hormones that modulate the expression of enzymes such as tyrosine hydroxylase (TH), dopamine-β-hydroxylase (DBH), tryptophan hydroxylase (TRH), MAO, catechol-O-metyltransferase (COMT), aldehyde dehydrogenase (AD), aldehyde reductase (AR) which are necessary for the synthesis and metabolism of these neurotransmitters[11-18]. To this effect, after prenatal and postnatal exposure to chlordimeform, we observed a disruption in testosterone and estradiol levels in frontal cortex and striatum, which may be responsible of changes in the expression of TH and TRH[20,21]. In this way, these mechanisms could explain chlordimeform's, as well as other formamidine pesticides' effects observed on monoaminergic neurotransmitters systems.

Therefore, we performed a study to determine if maternal exposure to chlordimeform during gestation and lactation induces permanent alterations on the enzymes that produce and metabolize 5-HT, NE and DA neurotransmitters in hippocampus at adult age, through sex hormones disruption, which could explain the effect observed on these neurotransmitters in a sex –and region– dependent way. Chlordimeform was chosen because it is the most representative compound of formamimidines family, all of which are weak MAO inhibitors. This allows us a clearer study whether the permanent changes observed on levels of these neurotransmitters are caused by an alteration of the enzymes that catalyse the synthesis and metabolism of these neurotransmitters rather than to MAO inhibition.

Materials and methods

Biological material
All experiments were performed in accordance with European Union guidelines (2003/65/CE) and Spanish regulations (BOE 67/8509-12, 1988) regarding the use of laboratory animals. Eight pregnant Wistar rats were housed individually in polycarbonate cages and were assigned randomly to two experimental groups: a chlordimeform treatment group (n = 4) and a control group (n = 4).

Test Chemical and Treatment

Chlordimeform (Sigma, Madrid, Spain) was dissolved in corn oil to provide fast and complete absorption and was administered orally by gavage in a volume of 2 mg/ml. The animals received, daily, chlordimeform at the dose of 5 mg/kg on days 6 to 21 of pregnancy (GD 6-21) and on days 1 to 10 of lactation (PN 1-10). Control dams received vehicle (corn oil 2.5 ml/kg) on the same schedules. Dose of chlordimeform was selected based on a previous preliminary study that indicated that this dose was the higher one that did not cause weight loss or mortality, reduction of food or water intake as well as did not induce haematological modifications or other clinical histopathological signs of overt toxicity. None of the prenatal or postnatal treatment evoked a significant change in weight of hippocampus on PN 60 (data not shown).

Dams were examined daily throughout the gestation and lactation periods for mortality, general appearance and behaviour. The maternal body weights were measured on GD 1, GD 5, GD 6, GD 15 and GD 20. Food and water consumption during pregnancy, length of gestation, litter size and sex ratio were also assessed.

On PN1, all litters were examined externally, sexed and weighed. Litters were organized in groups of twenty-four pups, twelve males and twelve females. Litters were weighed at PN 1, PN 7, PN14 and PN 21. The offspring were weaned on lactation day 21 and were maintained in appropriate conditions, housed individually and without any treatment with full access to food and water until adult age. The study was organized in treated groups of six males and six females randomly selected respectively from the dams' litters exposed to chlordimeform, and control groups of six males and six female's pups randomly selected respectively from the control dams' litters. At PN11, for the analysis of brain's testosterone and estradiol levels and at PN 60, for the analysis of MAO A, MAO B, COMT, BDH, AD, TH and TRH gene expression, male and female rats from control and treated groups (pups from control dams, and pups from dams exposed to chlordimeform, respectively) were sacrificed by decapitation. The brain was removed quickly and the hippocampus was a rapidly dissected out at 4ºC[22], since this brain region was previously describe to present sex differences in the effect observed on these neurotransmitters systems and to be one of the most affected[2,3]. Tissues were rapidly weighed and stored at -80ºC until analysis. All data were collected by experimenters blind to the treatment condition of the offspring.

Estradiol and testosterone quantification

Estradiol and testosterone content were measured in hippocampus from treated animals in order to determine whether sex hormones are altered by chlordimeform exposure. Estradiol and testosterone content in the hippocampus was measured using an enzyme immunoassay kit (Estradiol EIA Kit, Cayman Chemical Company,

MI, USA), according to the manufacturer's instruction. Tissues were homogenized in 300 μl of an equal mixture of ethyl acetate and 0.1 M phosphate-buffered saline. The homogenates were centrifuged at 21,000 g for 15 min at 4ºC. The resulting mixture was then incubated in a MeOH/dry ice bath to solidify the aqueous phase (bottom) and the organic phase was eluted into a new tube. The ethyl acetate portion was collected and dried. The dried material was reconstituted in 120 μl EIA buffer, and 100 μl of the sample was used for EIA at duplicate. ELISA values were obtained (pg/ml) and corrected for weigh tissue (mg/ml), producing a final unit of pg/mg and presented as a percentage of the untreated control.

Real-time PCR analysis

The MAOA, MAOB, COMT, AD, TH, TRH and DBH expression was measured in hippocampus tissue from control and chlordimeform treated animals in order to determine whether chlordimeform, through sex hormones disruption, alters permanently the expression of these enzymes. Total RNA was extracted using the Trizol Reagent method (Invitrogen, Madrid, Spain). The final RNA concentration was determined using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Madrid, Spain), and the quality of total RNA samples was assessed using an Experion LabChip (Bio-Rad, Madrid, Spain) gel. First-strand cDNA was synthesized with 1000 ng of cRNA by using a PCR array first strand-synthesis kit (C-02; Super-Array Bioscience, Madrid, Spain) in accordance with the manufacturer's instructions and including a genomic DNA elimination step and external RNA controls. After reverse transcription, QPCR was carried out using prevalidated primer sets (SuperArray Bioscience) for mRNAs encoding MAOA (PPR46359A), COMT (PPR06789A), AD (PPPR43520B), TH (PPR45220F), TRH (PPR48244A), DBH (PPR52652A), and ACTB (PPM02945B). ACTB was used as an internal control for normalization. Reactions were run on a CFX96 using Real-Time SYBR Green PCR master mix PA-012 (SuperArray Bioscience). The thermocycler parameters were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 72°C for 30 seconds. Relative changes in gene expression were calculated using the Ct (cycle threshold) method. The expression data are presented as actual change multiples[23].

Data analysis

Statistical analysis of data was performed using a Statgraphics software, version Plus 4.1 for windows. Values are expressed as mean ± S.E.M. obtained from 12 animals, six males and six females, in each group (control and treated groups). For values combined for males and females, a two-way ANOVA with treatment × sex interaction was the initial test used. Where a significant treatment × sex interaction was detected, a separate Student's *t* test was carried out for each sex. The results were considered significant at $P<0.05$. Results significantly different from controls are also presented as change from control (%).

Results

Maternal and offspring body weight, physical and general activity development were unaffected by the exposure of dams to chlordimeform (5 mg/kg bw orally on days 6 to 21 of pregnancy and 1 to 10 of lactation).

Estradiol and testosterone quantification

Oral treatment with chlordimeform to dams during the gestation period from day 6 to day 21 and during lactation from day 1 to day 10 affected the content of T and E2 in the hippocampus region of offspring rats at the age of 11 days. The content of T (ng/g tissue) in the region of hippocampus in the control group and treated group is presented in **table I**. The content of E2 (ng/g tissue) in the region of the hippocampus of the control group and the treated group is presented in **table II**. The results expressed in **tables I** and **II** show that in 11 days old rats treated during gestation days 6-21 and during lactation days 1-10 through their mothers, a statistically significant loss of T content and a significant increase in E2 content in the hippocampus compared to control animals was produced. A sex interaction with treatment in the content of T and E2 was observed (**Figure 2**). In hippocampus, the increase observed of E2 content was 39,08%

(P<0,001) and 68,13% (P<0,001) in males and females, respectively, and the loss in the content of T was 16,97% (P<0,001) and 22,97% (P<0,001) in males and females, respectively (**Figure 2**).

Real-time PCR analysis

Oral treatment with chlordimeform to dams during the gestation period from day 6 to day 21 and during lactation from day 1 to day 10 affected the COMT, AD, TH and TRH gene expression of offspring rats at the age of 60 days. In 60 days old rats treated during gestation days 6-21 and during lactation days 1 to 10 an increase in the expression of COMT [67,39% (P<0,001) and 45,71% (P<0,001)], AD [24,62% (P<0,01) and 39,54% (P<0,001)] and TRH [52,72% (P<0,001) and 26,75% (P<0,01)] enzymes and a decrease in TH [63,45% (P<0,001) and 26,35% (P<0,01)] enzyme in males and females, respectively, in hippocampus with respect to control animals was observed. No effect on gene expression of MAO, and BDH enzymes was observed (**Figure 3**). A sex difference in COMT, AD, TH and TRH gene expression was observed, being higher the expression of COMT [58,83% (P<0,001)], AD [46,74% (P<0,001)], TH [43,65% (P<0,001)] and TRH [37,85% (P<0,001)] enzymes in female than in male rats (**Figure 4**).

Table I: Tissue T (pg/ml) content determined in striatum from male and female rats at 11 days of age treated with vehicle or chlordimeform (5 mg/kg bw orally on days 6 to 21 of pregnancy and 1 to 10 of lactation).

	Hippocampus			
Animal	Control group Males	Treated group Males	Control group Females	Treated group Females
1	301,43	253,57	305,87	232,65
2	296,87	256,18	298,76	231,67
3	309,65	254,84	296,16	226,86
4	295,96	248,76	302,87	229,76
5	310,65	247,87	294,76	228,87
6	304,74	249,36	301,76	236,81
Mean ± SEM	303,22±2,55***	251,76±1,44*** (-16,97%)	300,03±1,73***	231,10±1,41*** (-22,97)

Values are mean ± S.E.M.; control animals (n= 6 males, n= 6 females); treated group (n= 6 males, n= 6 females).
Statistical significance is reported for the ***P<0.001 levels compared with the control group.

Table II: Tissue E2 (pg/ml) content determined in striatum from male and female rats at 11 days of age treated with vehicle or chlordimeform (5 mg/kg bw orally on days 6 to 21 of pregnancy and 1 to 10 of lactation).

	Frontal Cortex			
Animal	Control group Males	Treated group Males	Control group Females	Treated group Females
1	83,40	132,34	75,67	124,76
2	93,43	125,45	83,31	128,74
3	101,34	136,26	77,51	135,82
4	92,61	129,71	81,75	132,87
5	103,41	132,45	73,93	137,75
6	96,45	137,43	78,54	131,78
Mean ± SEM	95,10±2,92***	132,27±1,79*** (39,08%)	78,45±1,46***	131,9±1,93*** (68,13%)

Values are mean ± S.E.M.; control animals (n= 6 males, n= 6 females); treated group (n= 6 males, n= 6 females).
Statistical significance is reported for the ***P<0.001 levels compared with the control group.

Discussion

Chemical exposure of dams during pregnancy or lactation could induce developmental neurotoxic effects that include alterations in behaviour, neurohistology, neurochemistry and/or gross dysmorphology of CNS, which are manifest in the adulthood. Previous studies described that formamidines induce permanent alteration in developing monoamine neurotransmitter systems in a sex –and region– dependent way[1-3]. Specifically, chlordimeform has been reported to induce an alteration of 5-HT, DA and NE neurotransmitters and their metabolites in a sex-dependent way in only the regions of frontal cortex, striatum and hippocampus[2,3]. The mechanism by which these permanent effects on monoaminergic systems take place is not completely understood, but monoamine neurotransmitters regulate brain development prior to assuming their roles as transmitters in the mature brain[24-26], thus any circumstance that affects these neurotransmitters in the developing brain can alter the final structure and function of that brain. Since the endogenous levels of 5-HT, DA and NE are highly regulated by MAO, any change in this enzyme can profoundly affect the developing brain. In this regard, it has been reported that gestational exposure to MAO inhibitors clorgyline and deprenyl produces in offspring at 30 days of age, a significant reduction of serotonergic innervation particularly in the frontal cortex[27], but not in the dopaminergic and noradrenergic

innervation, which suggests that besides MAO inhibition other mechanism should be implicated in the alteration observed. However, chlordimeform is a very weak MAO inhibitor[28-30], but presents similar permanent regional and sexual dependent effects than amitraz, which is a potent MAO inhibitor[9]. These data suggest that MAO inhibition could not produce the alterations in monoaminergic neurotransmitters systems observed, confirming that other mechanisms are involved.

Otherwise, steroids play a role in the development of catecholamine systems[31-34], and play a critical role in mammalian brain developmental of both genders[35]. The present study shows that prenatal and postnatal exposure to chlordimeform (5 mg/kg bw orally on days 6 to 21 of pregnancy and 1 to 10 of lactation) was not able to induce maternal toxicity, since during pregnancy maternal weight gain of treated rats was not modified. However, chlordimeform administered during pregnancy and lactation leads to a decrease in T levels and an increase in E2 levels at PN11, which is the critical period of time when sexual differentiation takes place, in male and female rats' brain. This treatment produced also a permanent reduction of the TH gene expression and a permanent induction of COMT, BDH and TRH gene expression, which catalyse the synthesis and metabolism of monoaminergic neurotransmitters, at 60 days of age in male and female rats' hippocampus. Previously, chlordimeform has

Figure 2: Tissue T and E2 (pg/ml) content determined in striatum from male and female rats at 11 days of age treated with vehicle or chlordimeform (5 mg/kg bw orally on days 6 to 21 of pregnancy and 1 to 10 of lactation).

been reported to decrease T and E2 levels at PN11 in frontal cortex[20] and striatum[21] and to decrease TH and TRH gene expression in frontal cortex[20] and COMT, BDH, TH y TRH in striatum[21] at PN60, which support the effect observed. The sex and region differences in the enzymes altered in this region correspond with the alteration observed on the monoaminergic neurotransmitters in this region, which could explain the effect observed.

Sex hormones' effect on monoaminergic and indolaminergic neurotransmitters in CNS includes synthesis, vesicular and/or synaptic release and metabolism regulation[37]. The sex hormones provenance in the brain, could be from gonads or from endogenous synthesis, as previously described, whose contribution to the final effect depends on the region and sex steroid hormone[37-40]. Estradiol alters the levels of enzymes that synthesize DA, NE and 5HT, as well as those that degrade these neurotransmitters[12,14,16,41-42]. E2 elevated mRNA levels of TH, the first and major rate limiting enzyme in catecholamine biosynthesis[42] and enhanced TRH mRNA expression[12]. In addition, T and DHT regulated the synthesis and metabolism of monoamines[17]. In this sense, T and DHT increased TH protein and COMT, MAO-A and MAO-B mRNAs[15]. In the same way, DHT decreased neurotransmitter turnover

of DOPAC/DA, MHPG/NE, and 5-HIAA/5-HT of gonadectomized animals[13]. These previous data support that the disruption in sex hormones observed, mediate the effects observed on these enzymes after chlordimeform treatment, and so, on the monoaminergic neurotransmitters. However, we cannot rule out that an alteration of monoaminergic neurotransmitters transporters, which have been shown to be regulated by estradiol[43-46], might contribute to the effect observed.

Furthermore, other possible mechanisms that may contribute to the permanent alterations observed on monoaminergic neurotransmitters systems could be a direct action of chlordimeform on neuronal cell replication, differentiation, axonogenesis and synaptogenesis and functional development of neurotransmitter systems, effects that could result in behavioural alterations observed in previous studies after developmental exposure to chlordimeform[47]. The loss of dopaminergic, serotoninergic and noradrenergic projections could also play an important role in the behavioural and motor alterations. In this regard, hippocampus participates in the regulation of learning and memory processes, among other actions[48-51], thus, it could be considered that these processes could be compromised by exposure during gestation and lactation to formamidines. Moreover,

Figure 4: Results from real-time PCR targeting MAO, COMT, BDH, AD, TH y TRH genes after chlordimeform treatment in male and female rats. MAO, COMT, BDH, AD, TH y TRH gene expression was compared to controls. Each bar represents mean ± SD of 6 samples. Levels were measured using QPCR. ACTB was used as an internal control. ***$p \leq 0.001$, **$p \leq 0.01$ significantly different from controls.

neural functions like affect, anxiety, mood, fear and cognitive function are modulated by estradiol, predominantly enhancing learning and memory, in addition to its well-documented role in reproduction[51]. Therefore, the neurotoxic effects observed by chlordimeform or amitraz exposure such as behavioral effects as hyperreactivity to external stimuli, aggressiveness, and motor incoordination, among others[47,53], could be mediated by the alteration observed in these neurotransmitters. Neurofunctional disorders such as schizophrenia, aggressive behaviour, autism spectrum disorder and attention deficit hyperactivity disorder has been associated with imbalance in dopamine and other neurotransmitters in the developing brain[54-59], so these alterations could also lead to development of some of these neurological disorders after formamidines exposure. Further studies are needed to test whether these other mech-

anisms described could be involved in the effects observed and to confirm that alteration of these neurotransmitter systems is the cause of some of these dysfunctions.

DA, 5-HT and NE systems alterations observed after chlordimeform exposure in the frontal cortex and striatum were similar between them[2,3], but not in the hippocampus[3]. Moreover, the testosterone and estradiol hormone levels disruption produced after chlordimeform exposure in the frontal cortex striatum was also similar except in the hippocampus, as well as the effect on monoaminergic neurotransmitters regulating enzymes gene expression. These results suggests that the mechanisms through which monoaminergic neurotransmitters systems are altered in the brain regions affected after chlordimeform exposure is produced by the alteration in the expression of these enzymes, mediated through sex hormones disruption. The differences observed could be explained through the differences showed in the T and E2 disruption and in the expression of the enzymes that regulate the synthesis and metabolism of these neurotransmitters. In addition, the effects observed on DA, 5-HT and NE systems after amitraz exposures were also the same as those observed after chlordimeform exposure[1], suggesting that these mechanisms are the same in chlordimeform and amitraz in particular, and in formamidines in general. Further studies are needed to confirm whether this mechanism and others, probably involved in these effects, are the same in all brain regions studied and for all formamidines.

Conclusions

To sumarize, our results suggest that the mechanism by which the alterations in the development of the monoaminergic neurotransmitter systems in hippocampus is mediated through disruption of estradiol and testosterone levels, which produced a permanent alteration of the expression of some of the enzymes that synthetize and metabolize these monoaminergic neurotransmitters. Further studies are needed to check if other hormones are also involved in these effects and to determine whether they act directly on expression of the affected enzymes or inducting other genes that can regulate their expression. Otherwise, it should be determined whether there

is a reduction in innervation in the regions affected that could also contribute to the effect observed. Moreover, it should be determined if all formamidines work in the same way and if these mechanisms are the same in all formamidines and in all of the brain regions affected by them. Due to the fact that monoaminergic neurotransmitters dysfunctions are related with appetite, affective, neurological and psychiatric disorders, behavioral studies of formamidines are also needed to clarify the outcomes of long-term alterations in these monoaminergic neurotransmitters systems. Right now, new formamidine molecules with therapeutic application are being developed. Until now, the risk assessment of the family of these compounds has been taken from the standpoint of carcinogenesis. Keeping in mind these results and our previous ones, it might be appropriate to reconsider the risk assessment of the members of this family based not only on their possible carcinogenic effects, but also in the neurotoxic effects during development mediated by endocrine disruption. The showed results are of great importance because they could lead to a better understanding of the mechanisms which are in charge of producing the neurotoxic alterations and should be incorporated into the risk assessment of pesticides formamidines group.

Compliance with ethical standards

All experiments were performed in accordance with European Union guidelines (2003/65/CE) and Spanish regulations (BOE 67/8509-12, 1988) regarding the use of laboratory animals.

Conflict of interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors would like to thank Margarita Lobo, Professor of Toxicology from the Universidad Complutense de Madrid for her counseling during the preparation of the present work.

References

1. Del Pino J, Martínez MA, Castellano VJ, Ramos E, Martínez-larrañaga MR, Anadón A. Effects of prenatal and postnatal exposure to amitraz on norepinephrine, serotonin and dopamine levels in brain regions of male and female rats. Toxicology. 2011; 287(1-3):145-52.

2. García JM, Alias P, Frejo MT, Anadon MJ, Capo MA, Del Pino J. Effects of prenatal and postnatal exposure to chlordimeform on serotonin levels in brain regions of adult's male and female rats. Medicina Balear. 2015; 30(1): 21-6

3. García JM, Frejo MT, Anadon MJ, Capo MA, Del Pino J. Permanent sexual and regional noradrenergic and dopaminergic systems impairment after prenatal and postnatal exposure to chlordimeform. 2015; 30(3): 12-8.

4. Buznikov GA, Shmukler YB, Lauder JM. From oocyte to neuron: do neurotransmitters function in the same way throughout development. Cell. Mol. Neurobiol. 1996; 16(5): 533-59.

5. Levitt P, Harvey JA, Friedman E, Simansky K, Murphy EH. New evidence for neurotransmitter influences on brain development. Trends Neurosci. 1997; 20(6):269-74.

6. Nicotra A, Schatten G. Propranolol, a beta-adrenergic receptor blocker, affects microfilament organization, but not microtubules, during the first division in sea urchin eggs. Cell Motil. Cytoskeleton. 1990; 16(3):182-9.

7. Nicotra A, Senatori O. Some characteristics of mitochondrial monoamine oxidase activity in eggs of carp (Cyprinus carpio) and rainbow trout (Salmo gairdneri). Comp. Biochem. Physiol. 1989; C92(2):401-404.

8. Lakshmana M, Raju TR. Endosulfan induces small but significant changes in the levels of noradrenaline, dopamine and serotonin in the developing rat brain and deficits in the operant learning performance. Toxicology. 1994; 91(2):139-50.

9. Aziz SA, Knowles CO. Inhibition of monoamine oxidase by the pesticide chlordimeform and related compounds. Nature. 1973; 242:417-8.

10. Bailey BA, Martin RJ, Downer RGH. Monoamine oxidase inhibition and brain catecholamine levels in the rat following treatment with chlordimeform. Pest Biochem Physiol. 1982; 17:293-300.

11. De Souza Silva MA, Mattern C, Topic B, Buddenberg TE, Huston JP. Dopaminergic and serotonergic activity in neostriatum and nucleus accumbens enhanced by intranasal administration of testosterone. Eur Neuropsychopharmacol. 2009; 19 (1): 53-63.

12. Donner N, Handa RJ. Estrogen receptor-beta regulates the expression of tryptophan hydroxylase 2 mRNA within serotonergic neurons of the rat dorsal raphe nuclei. Neuroscience. 209; 163: 705-18.

13. Handa RJ, Hejna GM, Lorens SA. Androgen inhibits neurotransmitter turnover in the medial prefrontal cortex of the rat following exposure to a novel environment. Brain Res. 1997; 751 (1): 131-8.

14. Luine VN, Rhodes JC. Gonadal hormone regulation of MAO and other enzymes in hypothalamic areas. Neuroendocrinology. 1983; 36: 235-41.

15. Purves-Tyson TD, Handelsman DJ, Double KL, Owens SJ, Bustamante S, Weickert CS. Testosterone regulation of sex steroid-related mRNAs and dopamine-related mRNAs in adolescent male rat substantia nigra. BMC Neurosci1. 2012; 3: 95.

16. Scardapane L, Cardinali DP. Effect of estradiol and testosterone on catecholmethyl transferase activity of rat superior cervical ganglion, pineal gland, anterior hypophysis and hypothalamus. J Neurotrans. 1977; 40: 81-6.

17. Thiblin I, Finn A, Ross SB, Stenfors C. Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids. Br J Pharmacol. 1999; 126 (6): 1301-6.

18. Lubbers LS, Zafian PT, Gautreaux C, Gordon M, Alves SE, Correa L, Lorrain DS, Hickey GJ, Luine V. Estrogen receptor (ER) subtype agonists alter monoamine levels in the female rat brain. J Steroid Biochem Mol Biol. 2010; 122 (5): 310-7.

19. Stoker TE, Goldman JM, Cooper RL, McElroy WK. Influence of chlordimeform on alpha-adrenergic receptor-associated mechanisms of hormonal regulation in the rat: pituitary and adrenocortical secretion. Toxicology. 1991; 69:257-68.

20. García JM, Moyano P, Frejo MT, Anadón MJ, Capó MA, Gómez G, Del Pino J. Effects of sex hormones disruption, after prenatal and postnatal exposure to chlordimeform, on monoaminergic neurotransmitters systems in female and male rat's prefrontal cortex. Medicina Balear 2016; 31(3): 8-11.

21. Moyano P, García JM, Frejo MT, Anadón MJ, Capó MA, Flores A, Pelayo A, Sola E, Del Pino J. Striatal alteration of monoaminergic neurotransmitters systems in rats, after prenatal and postnatal exposure to chlordimeform, through testosterone and estradiol disruption. Medicina Balear 2017; 32(2): 13-22.

22. Glowinski J, Iversen LL. Regional studies of catecholamines in the rat brain-I. The disposition of [3H] norepinephrine, [3H] dopamine and [3H]DOPA in various regions of the brain. J. Neurochem. 1966; 13:655-69.

23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-8.

24. Whitaker-Azmitia PM. Role of serotonin and other neurotransmitter receptors in brain development: basis for developmental pharmacology. Pharm. Rev. 1992; 43:553-61.

25. Di Pino G, Moessner R, Lesch KP, Lauder JM, Persico AM. Roles for serotonin in neurodevelopment: more than just neural transmission. Curr. Neuropharmacol. 2004; 2:403-17.

26. Ansorge MS, Morelli E, Gingrich JA. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviours in mice. J. Neurosci. 2008; 28(1):199-207.

27. Whitaker-Azmitia PM, Zhang X, Clarke C. Effects of gestational exposure to monoamine oxidase inhibitors in rats: preliminary behavioral and neurochemical studies. Neuropsychopharmacology. 1994; 11(2):125-32.

28. Neumann R, Voss G. MAO inhibition, an unlikely mode of action for chlordimeform. Experientia. 1977; 33: 23-4.

29. Robinson CP, Smith PW. Lack of involvement of monoamine oxidase inhibition in the lethality of acute poisoning by chlordimeform. J Toxicol Environ Health. 1977; 3(3): 565-8.

30. Hollingworth RM. Chemistry, biological activity, and uses of formamidine pesticides. Environ Health Perspect. 1976; 14: 57-69.

María José Anadón et al.

Hippocampal alteration of monoaminergic neurotransmitters biosynthesis and metabolism in CNS in rats,
after prenatal and postnatal exposure to chlordimeform, through sex hormones disruption

31. Stewart J, Rajabi H. Estradiol derived from testosterone in prenatal life affects the development of catecholamine systems in the frontal cortex in the male rat. Brain Res. 1994; 646(1):157-60.

32. Leret ML, Rua C, Garcia-Montojo M, Lecumberri M, González JC. Influence of metyrapone treatment during pregnancy on the development and maturation of brain monoaminergic systems in the rat. Acta Physiol (Oxf). 2009; 197(4):333-40.

33. Muneoka K, Kuwagata M, Ogawa T, Shioda S. Sex-specific effects of early neonatal progesterone treatment on dopamine and serotonin metabolism in rat striatum and frontal cortex. Life Sci. 2010; 87(23-26):738-42.

34. Pappas SS, Tiernan CT, Behrouz B, Jordan CL, Breedlove SM, Goudreau JL, Lookingland KJ. Neonatal androgen-dependent sex differences in lumbar spinal cord dopamine concentrations and the number of A11 diencephalospinal dopamine neurons. J Comp. Neurol. 2010; 518(13): 2.423-36.

35. Konkle ATM, McCarthy MM. Developmental time course of estradiol, testosterone, and dihydrotestosterone levels in discrete regions of male and female rat brain. Neuroendocrinology. 2011; 152(1): 223-35.

36. Meyers B, D'Agostino A, Walker J, Kritzer MF. Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats. Neuroscience. 2010; 165(3): 850-62

37. Hojo Y, Higo S, Ishii H, Ooishi Y, Mukai H, Murakami G, Kominami T, Kimoto T, Honma S, Poirier D, Kawato S. Comparison between hippocampus-synthesized and circulation-derived sex steroids in the hippocampus. Endocrinology. 2009; 150(11): 5.106-12.

38. Robel P, Bourreau E, Corpéchot C, Dang DC, Halberg F, Clarke C, Haug M, Schlegel ML, Synguelakis M, Vourch C. Neuro-steroids: 3 beta-hydroxy-delta 5-derivatives in rat and monkey brain. J Steroid Bioche. 1987; 27(4-6): 649-55.

39. Zwain IH, Yen SS. Dehydroepiandrosterone: biosynthesis and metabolism in the brain. Endocrinology. 1999; 140(2):880-7.

40. Zwain IH, Yen SS. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology.1999; 140(8): 3.843-52.

41. Luine VN, Khylchevskaya RI, McEwen BS. Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res. 1973; 86: 293-306.

42. Serova L, Rivkin M, Nakashima A, Sabban EL. Estradiol stimulates gene expression of norepinephrine biosynthetic enzymes in rat locus coeruleus. Neuroendocrinology. 2002; 75: 193-200.

43. Meyers B, Kritzer MF. In vitro binding assays using (3)H nisoxetine and (3)H WIN 35,428 reveal selective effects of gonadectomy and hormone replacement in adult male rats on norepinephrine but not dopamine transporter sites in the cerebral cortex. Neuroscience. 2009; 159(1): 271-82.

44. Rivera HM, Oberbeck DR, Kwon B, Houpt TA, Eckel LA. Estradiol increases Pet-1 and serotonin transporter mRNA in the midbrain raphe nuclei of ovariectomized rats. Brain Res. 2009; 1259: 51-8.

45. Yu PL, Wu CI, Lee TS, Pan WH, Wang PS, Wang SW. Attenuation of estradiol on the reduction of striatal dopamine by amphetamine in ovariectomized rats. J Cell Biochem 2009; 108(6): 1.318-24.

46. Le Saux M, Di Paolo T. Influence of oestrogenic compounds on monoamine transporters in rat striatum. J Neuroendocrinol. 2006; 18(1): 25-32.

47. Olson KL, Boush GM, Matsumura F. Behavioral effects of perinatal exposure of chlodimeform in rats. Bull Environ Contam Toxicol. 1978; 20(6):760-8.

48. Tewari A, Jog R, Jog MS. The Striatum and Subthalamic Nucleus as Independent and Collaborative Structures in Motor Control. Front Syst Neurosci. 2016;10:17.

49. González-Burgos I, Feria-Velasco A. Serotonin/dopamine interaction in memory formation. Prog Brain Res. 2008; 172:603-23.

50. Ohno Y, Shimizu S, Tokudome K. Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions. Biol Pharm Bull. 2013; 36(9):1.396-400.

51. Dunnet SB, Meldrum A, Muir JL. Frontal-striatal disconnection disrupts cognitive performance of the frontal-type in the rat. Neuroscience. 2005; 135:1.055-65.

52. Jacome LF, Gautreaux C, Inagaki T, Mohan G, Alves S, Lubbers LS, Luine V. Estradiol and ERβ agonists enhance recognition memory, and DPN, an ERβ agonist, alters brain monoamines. Neurobiol Learn Mem. 2010; 94(4): 488-498.

53. Florio JC, Sakate M, Palemo-Neto J. Effects of amitraz on motor function. Pharmacol Toxicol. 1993; 73: 109-14.

54. Casanova MF, Buxhoeveden D, Gomez J. Disruption in the inhibitory architecture of the cell minicolumn: implications for autism. Neuroscientist. 2003; 9: 496-507.

55. Martineau J, Barthelemy C, Jouve J, Muh JP, Lelord G. Monoamines (serotonin and catecholamines) and their derivatives in infantile autism: age-related changes and drug effects. Dev. Med. Child Neurol. 1992; 34: 593-603.

56. Robinson PD, Schutz CK, Macciardi F, White BN, Holden JJ. Genetically determined low maternal serum dopamine beat-hydroxylase levels and the etiology of autism spectrum disorders. Am. J. Med. Genet. 2001; 100; 30-6.

57. Volkmar FR. Pharmacological interventions in autism: theoretical and practical issues. J. Clin. Child Psychol. 2001; 30: 80-7.

58. Insel TR, Zohar J, Benkelf ATC, Murphy DL. Serotonin in obsessions, compulsions, and the control of aggressive impulses. Ann. N. Y. Acad. Sci. 1990; 600:574-85.

59. Stein DJ, Hollander E, Liebowitz MR. Neurobiology of impulsivity and the impulse control disorders. J. Neuropsychiatry Clin. Neurosci. 1993; 5(1):9-17.